Alnair Therapeutics is a preclinical stage precision oncology platform focusing on developing innovative approaches to treat difficult.
Alnair Therapeutics has raised $1.0M in total funding. The most recent round was Pre-Seed. The last funding was announced in June 2023.
Alnair Therapeutics's investors include Gaingels, OCA Ventures, Portal Innovations, George Shultz Innovation Fund, University of Chicago New Venture Challenge.
Alnair Therapeutics is headquartered in Chicago, United States.
Alnair Therapeutics is a preclinical stage precision oncology platform focusing on developing innovative approaches to treat difficult.
Alnair Therapeutics is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Alnair Therapeutics — Funding & Investors." VCBacked, June 30, 2023, https://www.vcbacked.co/company/alnair-therapeutics. Accessed August 23, 2026.
VCBacked. (2023). Alnair Therapeutics — Funding & Investors. Retrieved August 23, 2026, from https://www.vcbacked.co/company/alnair-therapeutics
{{cite web |title=Alnair Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/alnair-therapeutics |website=VCBacked |access-date=August 23, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated